Advertisement
Organisation › Details
Hookipa (Group)
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, selfantigens and next-generation antigens. *
Start | 2011-07-01 established | |
Industry | Vaxwave® technology | |
Industry 2 | HB-101 (Hookipa) | |
Person | Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH) | |
Region | Wien (Vienna) | |
Country | Austria | |
Street | 2 Helmut-Qualtinger-Gasse Campus Vienna Biocenter | |
City | 1030 Wien | |
Tel | +43-1-890-6360 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2023-02-28) |
Currency | USD | |
Annual sales | 15,249,000 (revenue, consolidated (2022) 2022-12-31) | |
Profit | -67,291,000 (2022-12-31) | |
Cash | 117,500,000 (2023-12-31) | |
* Document for »About Section«: Hookipa Pharma Inc.. (2/26/19). "Press Release: Hookipa Pharma Raises $37.4 Million (€33.2 Million) in Series D Financing". New York, NY & Vienna. | ||
Record changed: 2024-02-06 |
Advertisement
More documents for Hookipa (Group)
- [1] Valneva S.E.. (12/6/18). "Press Release: Valneva and Hookipa Sign a Collaboration and Manufacturing Agreement". Saint-Herblain & Vienna....
- [2] Hookipa Biotech AG. (12/11/17). "Press Release: Hookipa Biotech Raises $60 Million (€50 Million) in an Oversubscribed Round C Financing". Vienna....
- [3] Hookipa Biotech AG. (4/19/17). "Press Release: Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech". Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top